SENSEX
 
Home / Markets
EQUITY
 
BOARD MEETINGS
  
Glenmark Pharmaceuticals Ltd.
BSE CODE: 532296   |   NSE CODE: GLENMARK   |   ISIN CODE : INE935A01035
BSE
526.80
4.9 ( 0.94% )
 
Prev Close ( Rs.)
521.90
Open ( Rs.)
525.80
 
High ( Rs.)
532.50
Low ( Rs.)
517.60
 
Volume
74746
Week Avg.Volume
26566
 
52 WK High-Low Range(Rs.)
BSE NSE
525.75
2.55 ( 0.49% )
 
Prev Close ( Rs.)
523.20
Open ( Rs.)
523.20
 
High ( Rs.)
533.00
Low ( Rs.)
518.20
 
Volume
528225
Week Avg.Volume
445445
 
52 WK High-Low Range(Rs.)
518.2
711.9
Source DateBoard Meeting DateDetails
27-May-2019 29-May-2019 Rhe meeting of the Board of Directors of the Company scheduled on Wednesday, 29 May, 2019, will consider, apart from audited financial result and declaration of dividend, also consider the proposal to enable raising of funds through issue of debt securities whether denominated in Indian Rupee and/or foreign currency(ies) either by way of a public issue or by way of a private placement in accordance with the provisions of the applicable law, subject to necessary approvals, if any. Proceeds from these debt securities issuance will be used mainly to refinance existing debt.
14-May-2019 29-May-2019 Dividend & Audited Results
01-Feb-2019 14-Feb-2019 Quarterly Results
02-Nov-2018 13-Nov-2018 Quarterly Results
25-Sep-2018 28-Sep-2018 Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of Glenmark Pharmaceuticals Limited (?Company?) will be held on September 28, 2018, to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million 2 per cent resettable onward starting equity linked securities due June 28, 2022 issued in 2016 (?FCC Bonds?) and / or, its U.S.$200 million 4.5% senior notes due 2021 issued in 2016 (?FCY Bonds?), based on market opportunities and conditions from time to time and to delegate powers to operations committee. The Operations Committee, based on market opportunities and conditions, will hold meetings during the next one month to consider and approve the terms and conditions of any tenders or buybacks.
30-Jul-2018 10-Aug-2018 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2018 ,inter alias, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2018. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from July 1, 2018 to August 12, 2018 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2018.
16-May-2018 29-May-2018 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, May 29, 2018, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2018 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2018. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from April 1, 2018 to May 31, 2018 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the year ended March 31, 2018. The above is for your information.
30-Jan-2018 08-Feb-2018 Quarterly Results
23-Oct-2017 02-Nov-2017 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, November 2, 2017, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half year ended September 30, 2017. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 25, 2017 to November 6, 2017 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half year ended September 30, 2017. The above is for your information.
13-Jul-2017 27-Jul-2017 Quarterly Results
Page 1 of 8
PREV || NEXT

Attention Investors:

Prevent unauthorised transactions in your account --> Update your Mobile numbers/Email IDs with your stock broker / DP. Receive information of your transactions directly from Exchange / Depository on your Mobile/Email at the end of the day. "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
BSE NSE SEBI MCX MCX-SX
Help DeskDepositoryDisclaimerPrivacy PolicyAdmin Login
SEBI Registration Number:
NSE: Member ID -12252, SEBI Reg - INZ000213936
BSE: Member ID -3055, SEBI Reg - INZ000213936
NCDEX: Member ID -00739, SEBI Reg -INZ000086834
MCX: Member ID -31160, SEBI Reg -INZ000086834
MCX-SX: Member ID -39800, SEBI Reg - INZ000213936
SEBI Scores

© Copyright Almondz Global Securities Ltd. All Rights Reserved
Designed, Developed and Content Provided by Accord Fintech Pvt. Ltd.
Visitors counter: 33159308